IC
ICUI.US ICU Medical Inc
- Market cap
- USD 4.48B
- P/E
- 75.0x
- P/B
- 2.05x
- ROE
- 4.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ICUI.US undervalued?
Graham numberICUI.US trades 161.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ICU Medical Inc fundamental analysis
No fundamental analysis for ICU Medical Inc yet.
ICU Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ICU Medical Inc
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-co…
Full company profileICU Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ICU Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 379M | 1.29B | 1.40B | 1.27B | 1.27B | 1.32B | 2.28B | 2.26B | 2.38B | 2.23B | 2.19B |
| Gross Profit | 201M | 426M | 570M | 472M | 461M | 491M | 698M | 740M | 825M | 820M | 857M |
| Operating Income | 82.9M | -15.1M | 21.6M | 107M | 98.2M | 123M | -42.9M | 22.8M | 43.0M | 107M | 163M |
| EBITDA | 118M | 206M | 272M | 192M | 194M | 214M | 192M | 253M | 260M | 309M | 299M |
| Net Income | 63.1M | 68.6M | 28.8M | 101M | 86.9M | 103M | -74.3M | -29.7M | -118M | 732K | 101M |
| EPS | 3.66 | 3.29 | 1.33 | 4.69 | 4.02 | 4.74 | -3.11 | -1.23 | -4.83 | 0.03 | 4.03 |
| Balance Sheet | |||||||||||
| Total Assets | 705M | 1.50B | 1.59B | 1.69B | 1.76B | 1.88B | 4.52B | 4.38B | 4.20B | 4.05B | 3.94B |
| Total Liabilities | 44.5M | 299M | 322M | 315M | 261M | 265M | 2.43B | 2.26B | 2.24B | 1.93B | 1.75B |
| Shareholders' Equity | 660M | 1.20B | 1.26B | 1.38B | 1.50B | 1.62B | 2.09B | 2.12B | 1.97B | 2.12B | 2.19B |
| Cash & Short-term Investments | 445M | 300M | 382M | 293M | 411M | 567M | 213M | 255M | 309M | 308M | 302M |
| Total Debt | - | - | - | 36.3M | 52.7M | 45.0M | 1.73B | 1.70B | 1.64B | 1.39B | 1.15B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 89.9M | 154M | 160M | 102M | 223M | 268M | -62.1M | 166M | 204M | 180M | 292M |
| Capital Expenditure | 24.6M | 79.7M | 101M | 106M | 100M | 81.2M | 99.3M | 93.7M | 79.4M | 88.0M | 61.3M |
| Free Cash Flow | 65.4M | 74.7M | 59.4M | -4.12M | 122M | 186M | -161M | 72.5M | 125M | 91.8M | 230M |
| Ratios | |||||||||||
| ROE | 9.6% | 5.7% | 2.3% | 7.3% | 5.8% | 6.4% | -3.6% | -1.4% | -6.0% | 0.0% | 4.6% |
| ROA | 9.0% | 4.6% | 1.8% | 6.0% | 4.9% | 5.5% | -1.6% | -0.7% | -2.8% | 0.0% | 2.6% |
| Net Profit Margin | 16.6% | 5.3% | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% | 4.6% |
| Debt to Equity | - | - | - | 0.03x | 0.04x | 0.03x | 0.83x | 0.80x | 0.84x | 0.66x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ICU Medical Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 9.35M | 0.39 | - |
| 2022 | USD 10.9M | 0.46 | - |
| 2021 | USD 1.04M | 0.05 | 1.0% |
| 2020 | USD 317K | 0.01 | 0.4% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Mar 18, 2002.
Who owns ICU Medical Inc
- Insiders 1.94%
- Institutions 98.06%
- Public & others 0.00%
- Shares outstanding 25.0M
- Free float 24.6M
Top funds holding ICUI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.50M | 6.01% | -0.08% | Oct 2026 |
| Janus Henderson Enterprise D | 1.23M | 4.92% | 0.00% | Sep 2026 |
| Undiscovered Managers Behavioral Val L | 882K | 3.53% | -7.61% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 797K | 3.19% | +0.36% | Sep 2026 |
| iShares Russell 2000 ETF | 626K | 2.50% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 562K | 2.25% | -2.29% | Sep 2026 |
| Janus Henderson Triton D | 375K | 1.50% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 366K | 1.46% | +0.32% | Sep 2026 |
| DFA U.S. Small Cap Value I | 347K | 1.39% | +52.81% | Sep 2026 |
| Victory Sycamore Small Company Opp R | 295K | 1.18% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 270K | 1.08% | +0.16% | Aug 2026 |
| Thrivent Small Cap Stock A | 256K | 1.02% | -0.04% | Sep 2026 |
| iShares Russell 2000 Value ETF | 232K | 0.93% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 228K | 0.91% | -0.05% | Oct 2026 |
| Janus Henderson Venture D | 222K | 0.89% | 0.00% | Sep 2026 |
| Nomura Small Cap Value A | 211K | 0.84% | 0.00% | Sep 2026 |
| Oberweis Small-Cap Opportunities | 200K | 0.80% | +16.85% | Jun 2026 |
| Bridge Builder Small Cap Fund | 189K | 0.76% | +5.66% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 161K | 0.64% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 144K | 0.57% | +1.14% | Sep 2026 |
Top institutions holding ICUI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 3.75M | 15.01% | +4.02% | Jun 2026 |
| Jupiter Topco LLC | 2.78M | 11.12% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.47M | 5.88% | +2.29% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 1.30M | 5.19% | +6.36% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.12M | 4.49% | +1.02% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.10M | 4.38% | +4.07% | Sep 2026 |
| State Street Corp | 1.02M | 4.10% | +5.82% | Jun 2026 |
| Schroder Investment Management Group | 739K | 2.96% | +5.40% | Jun 2026 |
| Ameriprise Financial Inc | 690K | 2.76% | +13.84% | Jun 2026 |
| Geode Capital Management, LLC | 660K | 2.64% | +8.05% | Jun 2026 |
| River Road Asset Management, LLC | 626K | 2.50% | -3.12% | Jun 2026 |
| Citadel Advisors Llc | 536K | 2.14% | +60.87% | Jun 2026 |
| Neuberger Berman Group LLC | 451K | 1.80% | +1.09% | Jun 2026 |
| JPMorgan Chase & Co | 440K | 1.76% | -5.85% | Jun 2026 |
| The Goldman Sachs Group Inc | 417K | 1.67% | +29.33% | Jun 2026 |
| Thrivent Financial For Lutherans | 381K | 1.52% | -12.08% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 373K | 1.49% | -29.28% | Jun 2026 |
| Bank of America Corp | 369K | 1.47% | +11.16% | Jun 2026 |
| The Toronto-Dominion Bank | 358K | 1.43% | +71.36% | Jun 2026 |
| Charles Schwab Investment Management Inc | 331K | 1.32% | +2.66% | Jun 2026 |
ICU Medical Inc company profile
- Company name
- ICU Medical Inc
- Ticker
- ICUI.US
- Exchange
- USA Stocks
- Listed since
- Mar 31, 1992
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 13,000
- Fiscal year end
- December
- Address
- 951 Calle Amanecer, San Clemente, CA, United States, 92673
- Phone
- 949 366 2183
- Website
- icumed.com
About ICU Medical Inc
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
ICU Medical Inc management
7- Mr. Vivek JainCEO & Chairman of the Board · born 1972
- Mr. Daniel WoolsonPresident · born 1977
- Mr. Brian Michael BonnellCFO & Treasurer · born 1974
- Mr. Christian B. VoigtlanderChief Operating Officer · born 1968
- Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer · born 1975
- Ben SousaChief Information Officer
- Olivia BarrallVice President of Human Resources